BioXcel Therapeutics (BTAI) Other Accumulated Expenses (2018 - 2026)

BioXcel Therapeutics' Other Accumulated Expenses history runs 9 years deep, the most recent figure standing at $2.3 million for Q1 2026.

• On a quarterly basis, Other Accumulated Expenses rose 454.85% year-over-year to $2.3 million in Q1 2026; TTM through Mar 2026 was $2.3 million, a 454.85% increase from a year earlier, with the FY2025 full-year figure at $622000.0, up 93.17% from the prior year.
• Other Accumulated Expenses grew to $2.3 million in Q1 2026 per BTAI's latest filing, from $622000.0 in the prior quarter.
• Across five years, Other Accumulated Expenses topped out at $2.3 million in Q1 2026 and bottomed at $152000.0 in Q1 2022.
• The 5-year median for Other Accumulated Expenses is $366000.0 (2025), against an average of $512235.3.
• Across the five-year window, Other Accumulated Expenses slumped 78.41% in 2023 and surged 454.85% in 2026, its largest moves.
• Year by year, Other Accumulated Expenses stood at $820000.0 in 2022, then slumped by 78.41% to $177000.0 in 2023, then jumped by 81.92% to $322000.0 in 2024, then jumped by 93.17% to $622000.0 in 2025, then surged by 277.33% to $2.3 million in 2026.
• Per Business Quant, the three latest BTAI Other Accumulated Expenses figures stand at $2.3 million (Q1 2026), $622000.0 (Q4 2025), and $450000.0 (Q3 2025).